PFIZER LTD.

Pfizer Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is in preparation for the declaration of unaudited financial results for the half-year ending September 30, 2026. The trading window will be shut from Wednesday, September 30, 2026, effective at the close of business, and will reopen 48 hours after the financial results are officially published. This measure is standard practice to prevent insider trading ahead of significant financial disclosures.

Pfizer Ltd has received an order from the Deputy/Additional Commissioner of Income Tax Transfer Pricing, levying a penalty of ₹1,26,34,050 for the Assessment Year 2023-24. The penalty is based on a Transfer Pricing audit, allegedly due to non-furnishing of specific granular information. The company believes the order is not maintainable and plans to appeal. Pfizer states the order has no material impact on its financials, operations, or other activities.

Pfizer Ltd has announced the resignation of Mr. Sharad Goswami, Senior Director – Policy & Public Affairs. His resignation is effective from September 25, 2026, close of business. Mr. Goswami is leaving to pursue opportunities outside of Pfizer Limited and will consequently cease to be a Senior Management Personnel from the effective date. The company has provided additional details as per SEBI regulations, confirming the reason for change and the cessation date.

Pfizer Ltd announced that it will discontinue the marketing, distribution, and sale of Minipress XL effective September 7, 2026. This decision follows Pfizer Inc. USA's discontinuation of Minipress XL manufacturing. In connection with this, Pfizer Ltd will receive a one-time payment of USD 13.9 Million (approximately Rs. 131.38 Crore) from Pfizer Inc. USA. The board meeting where this outcome was decided commenced at 10:33 a.m. and concluded at 11:03 a.m. on September 7, 2026.

Pfizer Limited (standalone; the company has no subsidiaries) reported Q1 FY27 net profit of ₹204.47 crore, up 6.6% from ₹191.75 crore a year ago and up 2.3% sequentially. Revenue from operations rose 8.3% YoY to ₹653.17 crore, a steady single-digit print for the single-segment pharma company, with profit before tax at ₹276.68 crore. There were no exceptional items this quarter, so the growth is clean — unlike FY26, which carried a ₹49.16 crore exceptional charge (₹41.73 crore of field-force separation cost tied to the Cipla supply-and-marketing pact for Corex Dx, Corex LS, Dolonex and Neksium, plus ₹7.43 crore of New Labour Code provisioning). The quality of the print is better than the headline PAT growth suggests. Core revenue grew 8.3% while other income actually fell a third, from ₹67.17 crore to ₹44.84 crore, so total income was up only 4.1% YoY — meaning the profit gain was driven by the operating business rather than treasury income. Net margin on total income expanded to ~29.3% from ~28.6% a year ago (though a touch below last quarter's ~29.8%), and NPM on core revenue sits above 31%. Operating profitability held despite higher purchases of stock-in-trade (₹182.89 crore vs ₹124.28 crore YoY), indicating the sales-mix shift toward traded goods rather than in-house manufacture. The result lands alongside two corporate developments worth flagging: CFO Amit Agarwal has resigned effective October 8, 2026, opening a finance-leadership transition; and the company has temporarily discontinued Premarin Vaginal Cream in India. Neither dents this quarter's numbers, but the CFO exit is a governance watch item into H2. The board earlier recommended a ₹75 FY26 dividend, and the 75th AGM is today. Management provides no formal quarterly guidance and gives no outlook in the filing; on the street side, no published consensus PAT/EPS estimate for the quarter surfaced (near-term price targets are framed only as contingent on results 'meeting expectations'), so vs-street is left unknown rather than invented.

Pfizer Ltd has announced the resignation of Mr. Amit Agarwal, Executive Director – Finance & Chief Financial Officer, effective October 8, 2026. Mr. Agarwal is stepping down to pursue an opportunity outside the company. He will also cease to be a Director on the Board and a member of the Corporate Social Responsibility Committee, Risk Management Committee, and Board Administrative & Share Transfer Committee. The company has provided additional details as per SEBI regulations.

Pfizer Ltd has announced that its Board of Directors will convene on July 28, 2026. The primary agenda item is to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026. In line with SEBI regulations, the trading window for the company's shares will remain closed from June 30, 2026, until 48 hours after the financial results are publicly disclosed on July 28, 2026. This notice ensures compliance with insider trading regulations.

Pfizer Ltd has responded to a clarification request regarding a news item about the discontinuation of Premarin Vaginal Cream in India. The company stated that the imported product has been temporarily suspended due to supply constraints and that they are actively working to restore supply. Pfizer emphasized that Premarin Vaginal Cream contributes less than 1% to the company's revenue and its temporary discontinuation is not expected to have a material impact on financial performance, business operations, or profitability. The company also clarified that this event did not constitute a material event requiring disclosure under SEBI regulations.

Pfizer Limited has informed shareholders about the availability of its Annual Report for the financial year 2025-26. A letter containing the weblink to access the report has been sent to shareholders whose email addresses are not registered. The company also announced its 75th Annual General Meeting (AGM) scheduled for July 28, 2026, to be held via Video Conferencing. The AGM notice, along with the Annual Report, was electronically sent to registered shareholders on July 6, 2026. Key dates for dividend payment and e-voting have also been provided, including a final dividend of ₹75 per equity share.

Pfizer Ltd has announced its 75th Annual General Meeting (AGM) will be held on July 28, 2026, via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company will submit its Annual Report for the Financial Year ended March 31, 2026, and the AGM Notice will be sent electronically to members. The Board of Directors has recommended a final dividend of Rs. 75/- per equity share, subject to member approval at the AGM. The dividend, if approved, will be paid on or after August 4, 2026. The agenda includes adoption of financial statements, declaration of dividend, appointment of a director, and ratification of remuneration for cost accountants.